JP2024537394A5 - - Google Patents

Info

Publication number
JP2024537394A5
JP2024537394A5 JP2024522487A JP2024522487A JP2024537394A5 JP 2024537394 A5 JP2024537394 A5 JP 2024537394A5 JP 2024522487 A JP2024522487 A JP 2024522487A JP 2024522487 A JP2024522487 A JP 2024522487A JP 2024537394 A5 JP2024537394 A5 JP 2024537394A5
Authority
JP
Japan
Prior art keywords
amino
diazepine
thieno
triazolo
cpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537394A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/125080 external-priority patent/WO2023061440A1/en
Publication of JP2024537394A publication Critical patent/JP2024537394A/ja
Publication of JP2024537394A5 publication Critical patent/JP2024537394A5/ja
Pending legal-status Critical Current

Links

JP2024522487A 2021-10-14 2022-10-13 修飾タンパク質およびタンパク質分解剤 Pending JP2024537394A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/123848 2021-10-14
CN2021123848 2021-10-14
CNPCT/CN2021/133363 2021-11-26
CN2021133363 2021-11-26
PCT/CN2022/125080 WO2023061440A1 (en) 2021-10-14 2022-10-13 Modified proteins and protein degraders

Publications (2)

Publication Number Publication Date
JP2024537394A JP2024537394A (ja) 2024-10-10
JP2024537394A5 true JP2024537394A5 (https=) 2025-10-21

Family

ID=85987275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522487A Pending JP2024537394A (ja) 2021-10-14 2022-10-13 修飾タンパク質およびタンパク質分解剤

Country Status (9)

Country Link
US (1) US20250235543A1 (https=)
EP (1) EP4416145A1 (https=)
JP (1) JP2024537394A (https=)
CN (1) CN118451078A (https=)
AU (1) AU2022362494A1 (https=)
CA (1) CA3234615A1 (https=)
IL (1) IL312013A (https=)
MX (1) MX2024004525A (https=)
WO (1) WO2023061440A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
US20260092062A1 (en) * 2022-09-26 2026-04-02 Rectify Pharmaceuticals, Inc. Pyridine carboxamide compounds and their use in treating medical conditions
CN121005703A (zh) * 2024-05-24 2025-11-25 中国科学院广州生物医药与健康研究院 一种酰胺吲嗪类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3445765A4 (en) * 2016-04-22 2019-09-18 Dana Farber Cancer Institute, Inc. DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
EP3807272A1 (en) * 2018-06-13 2021-04-21 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
US20220002291A1 (en) * 2018-11-02 2022-01-06 The Wistar Institute Of Anatomy And Biology Proteolysis-targeting chimeras
WO2020173440A1 (en) * 2019-02-27 2020-09-03 Cullgen (Shanghai), Inc. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use
WO2020206608A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
WO2020219650A1 (en) * 2019-04-23 2020-10-29 Dana-Farber Cancer Institute, Inc. Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof
CN112409376A (zh) * 2019-08-20 2021-02-26 华东师范大学 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用
CN120623106A (zh) * 2019-09-30 2025-09-12 协和麒麟株式会社 Bet降解剂
WO2021239117A1 (en) * 2020-05-28 2021-12-02 Cullgen (Shanghai) , Inc. Modified proteins and protein degraders

Similar Documents

Publication Publication Date Title
JP2024537394A5 (https=)
RU2472797C2 (ru) ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2013510122A5 (https=)
JP2015511629A5 (https=)
RU2001114978A (ru) N-ариламиды антраниловой кислоты и тиоантраниловой кислоты
JP2016506387A5 (https=)
RU2003114740A (ru) Азотсодержащие ароматические производные
RU2008100606A (ru) Ингибиторы сфингозинкиназы
RU2019136279A (ru) C5 -Анилинохиназолиновые соединения и их использование в лечении рака
RU2006146632A (ru) Производные хиназолинона, полезные в качестве ванилоидных антагонистов
RU2011152891A (ru) Диарилгидантоины
RU2007132161A (ru) Замещенные ариламины и их применение в качестве модуляторов 5-ht6-рецептора
JP2008535871A5 (https=)
RU2004130488A (ru) Пиримидиновые производные
CA2660529A1 (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
RU2007148217A (ru) Получение производных n-фенил-2-пиримидинамина
JP2011509309A5 (https=)
CA2436980A1 (en) Amido ether substituted imidazoquinolines
CA2392570A1 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines
JP2014502979A5 (https=)
EA200300424A1 (ru) Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
RU2009118254A (ru) Фенилацетамиды в качестве ингибиторов протеинкиназ
RU2007121219A (ru) Диазациклоалканы как агонисты окситоцина
RU2011130566A (ru) Сочетание ингибиторов аврора киназы и анти-cd 20 антител